Research Article Details
| Article ID: | A03910 |
| PMID: | 33822497 |
| Source: | Int J Med Mushrooms |
| Title: | Bioactive Components and Possible Activities of Medicinal Mushrooms in Alleviating the Pathogenesis of Nonalcoholic Fatty Liver Disease (Review). |
| Abstract: | Nonalcoholic fatty liver disease (NAFLD) is a global disease that is closely associated with obesity, type 2 diabetes mellitus, and cardiovascular disease. Excessive fat accumulation, fatty degeneration, and chronic inflammation of the liver activate the progression of NAFLD from simple steatosis to nonalcoholic steatohepatitis and further to liver fibrosis, cirrhosis, and hepatocellular carcinoma. The underlying mechanism for the development and progression of NAFLD is complex and a multiple-hit hypothesis including dietary, environmental, genetic, and epigenetic factors has been raised. Increased de novo lipogenesis, decreased lipolysis, and insulin resistance are associated with the development of NAFLD. Currently, no effective drug therapies are approved for the treatment of NAFLD. Several medicinal mushrooms have been found to have significant weight control and gut microbe modulation activities and antihypertriglyceridemic, antihyperglycemic, antioxidant, and anti-inflammatory effects, which may be useful to prevent and attenuate the development and progression of NAFLD. These beneficial effects are associated with mushrooms' bioactive components, such as polysaccharides, dietary fibers, antioxidants, and other compounds derived from fruiting bodies, cultured mycelium, and/or broth of medicinal mushrooms. This article presents an overview of multiple aspects of NAFLD, including the epidemiology, pathogenesis, management, and treatment. The bioactive components and possible activities of medicinal mushrooms in alleviating the pathogenesis of NAFLD are also reviewed. |
| DOI: | 10.1615/IntJMedMushrooms.2021037945 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| S07 | Anti-lipogenesis | de novo lipogenesis; de novo lipogenesis; DNL; anti-lipogenic mechanisms; adipogenesis; anti-obesity | stearoyl-CoA desaturase 1 (SCD-1); Acetyl-coenzyme carboxylase; acyl-CoA carboxylase inhibitor (ACC inhibitor); stearoyl Coenzyme A desaturase inhibitor (SCD inhibitor); THR-beta selective agonist; DGAT2 inhibitor; FASN inhibitor | Aramchol; Firsocostat (GS-0976); VK-2809; ION 224 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |